Loading...
XNAS
LIVN
Market cap4.53bUSD
Jul 09, Last price  
82.52USD
1D
0.01%
1Q
31.44%
Jan 2017
83.50%
IPO
28.64%
Name

LivaNova PLC

Chart & Performance

D1W1MN
XNAS:LIVN chart
P/E
—
P/S
3.27
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.32%
Rev. gr., 5y
8.24%
Revenues
1.39b
+10.74%
123,441,575130,968,437121,229,742143,600,979167,775,672190,464,398218,502,731254,320,417282,014,160291,557,9981,213,900,0001,012,300,0001,107,000,0001,084,170,000934,241,0001,035,365,0001,021,805,0001,153,545,0001,253,437,0001,388,100,000
Net income
-243m
L
-59,069,192-51,180,107-10,334,76526,720,62078,448,88446,725,71036,077,73246,357,50254,890,25757,847,534-62,800,000-25,100,000-189,400,000-157,639,000-348,819,000-135,818,000-86,246,00017,546,00063,234,000-242,500,000
CFO
254m
+38.93%
-70,876,209-20,688,85614,455,20724,589,95042,885,48649,872,10775,026,16579,053,75954,195,81679,675,11690,200,00091,300,000120,500,000-91,142,000-79,400,000102,544,00069,900,00074,914,000183,038,000254,300,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
URL
https://www.livanova.com/en-us
IPO date
Oct 19, 2015
Employees
2,900
Domiciled in
GB
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT